Sutro Biopharma Announces Presentation of STRO-002 for the Potential Treatment of Ovarian and Endometrial Cancer at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

On Octobber 16, 2019 Sutro Biopharma, Inc. (NASDAQ: STRO) reported that the company will present at the upcoming AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) being held Oct. 26-30, 2019, in Boston (Press release, Sutro Biopharma, OCT 16, 2019, View Source [SID1234542305]). The presentation will include both new preclinical efficacy data and initial dose escalation safety data from the company’s ongoing Phase I study of STRO-002 in patients with ovarian cancer. STRO-002 is a novel antibody-drug conjugate (ADC) targeting the clinically validated folate receptor-α (FRα), an antigen known to be overexpressed in ovarian cancer. Sutro discovered and manufactures STRO-002 using its proprietary XpressCF+ cell-free protein synthesis technology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details:

Antitumor activity of STRO-002, a novel folate receptor-α (FRα) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary phase I dose escalation safety outcomes in patients with ovarian carcinoma (OC)

Date: Tuesday, Oct. 29, 2019

Time: 12:30 p.m. – 4:00 p.m. EDT

Location: Hall D, Hynes Convention Center, Boston, MA, United States

Poster Session: Tubulin-interacting Agents

Abstract Number: C095

The abstract was published today on the AACR (Free AACR Whitepaper) website. The poster will be accessible through the Clinical/Scientific Presentation and Publication Highlights page of the News section of the company’s website at www.sutrobio.com on the day of the poster presentation.